New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...

Practitioners opted to target only the injectable dosage forms of olanzapine and benzodiazepines. This decision was made based on the more pronounced pharmacokinetic properties of the parenteral ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1.

The notes of 85 outpatients initially prescribed either Zyprexa (38 patients) or a branded generic olanzapine (47 patients) were examined during the study period. Patients prescribed Zyprexa were ...